Alan L Crane - Net Worth and Insider Trading

Alan L Crane Net Worth

The estimated net worth of Alan L Crane is at least $248 Million dollars as of 2024-11-09. Alan L Crane is the Director, 10% Owner of Pandion Therapeutics Inc and owns about 3,621,894 shares of Pandion Therapeutics Inc (PAND) stock worth over $217 Million. Alan L Crane is also the Director of Momenta Pharmaceuticals Inc and owns about 586,342 shares of Momenta Pharmaceuticals Inc (MNTA) stock worth over $31 Million. Details can be seen in Alan L Crane's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Alan L Crane has not made any transactions after 2020-07-21 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Alan L Crane

To

Alan L Crane Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Alan L Crane owns 6 companies in total, including Pandion Therapeutics Inc (PAND) , Vaccinex Inc (VCNX) , and Dare Bioscience Inc (DARE) among others .

Click here to see the complete history of Alan L Crane’s form 4 insider trades.

Insider Ownership Summary of Alan L Crane

Ticker Comapny Transaction Date Type of Owner
PAND Pandion Therapeutics Inc 2020-07-21 director & 10 percent owner
VCNX Vaccinex Inc 2018-08-09 director
DARE Dare Bioscience Inc 2014-04-10 director & 10 percent owner
LIMIT LIMIT 2014-08-06 director
LIMIT LIMIT 2014-07-24 director
LIMIT LIMIT 2010-04-14 other: Former Director

Alan L Crane Latest Holdings Summary

Alan L Crane currently owns a total of 2 stocks. Among these stocks, Alan L Crane owns 3,621,894 shares of Pandion Therapeutics Inc (PAND) as of July 21, 2020, with a value of $217 Million and a weighting of 87.61%. Alan L Crane also owns 586,342 shares of Momenta Pharmaceuticals Inc (MNTA) as of January 10, 2007, with a value of $31 Million and a weighting of 12.39%.

Latest Holdings of Alan L Crane

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
PAND Pandion Therapeutics Inc 2020-07-21 3,621,894 60.05 217,494,735
MNTA Momenta Pharmaceuticals Inc 2007-01-10 586,342 52.48 30,771,228

Holding Weightings of Alan L Crane


Alan L Crane Form 4 Trading Tracker

According to the SEC Form 4 filings, Alan L Crane has made a total of 1 transactions in Pandion Therapeutics Inc (PAND) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Pandion Therapeutics Inc is the acquisition of 50,111 shares on July 21, 2020, which cost Alan L Crane around $901,998.

According to the SEC Form 4 filings, Alan L Crane has made a total of 0 transactions in Momenta Pharmaceuticals Inc (MNTA) over the past 5 years. The most-recent trade in Momenta Pharmaceuticals Inc is the sale of 49,700 shares on January 10, 2007, which brought Alan L Crane around $867,762.

Insider Trading History of Alan L Crane

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Alan L Crane Trading Performance

GuruFocus tracks the stock performance after each of Alan L Crane's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Alan L Crane is -38.63%. GuruFocus also compares Alan L Crane's trading performance to market benchmark return within the same time period. The performance of stocks bought by Alan L Crane within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Alan L Crane's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Alan L Crane

Average Return

No transaction record over 1 Year.

Outperforming Transactions

No transaction record over 1 Year.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 0.94 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -3.35 LIMIT LIMIT LIMIT LIMIT LIMIT

Alan L Crane Ownership Network

Ownership Network List of Alan L Crane

No Data

Ownership Network Relation of Alan L Crane

Insider Network Chart

Alan L Crane Owned Company Details

What does Pandion Therapeutics Inc do?

Who are the key executives at Pandion Therapeutics Inc?

Alan L Crane is the director & 10 percent owner of Pandion Therapeutics Inc. Other key executives at Pandion Therapeutics Inc include director & 10 percent owner Daniel J. Becker , 10 percent owner Mva Investors, Llc , and 10 percent owner Polaris Partners VIII, L.P. .

Pandion Therapeutics Inc (PAND) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Pandion Therapeutics Inc (PAND) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Pandion Therapeutics Inc (PAND) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Pandion Therapeutics Inc (PAND)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Pandion Therapeutics Inc Insider Transactions

No Available Data

Alan L Crane Mailing Address

Above is the net worth, insider trading, and ownership report for Alan L Crane. You might contact Alan L Crane via mailing address: C/o Polaris Partners, One Marina Park Drive, 10th Floor, Boston Ma 02210.